NKTX
Nkarta, Inc.
Key Financials
Operating Income
$-121997000
↑ 4.8%
Net Income
$-104084000
↑ 4.3%
Revenue
$0
NaN%
EPS (Diluted)
$-1.41
↑ 11.9%
Total Assets
$404.2M
↓ 19.4%
Total Liabilities
$91.9M
↓ 1.4%
Shareholders' Equity
$312.3M
↓ 23.4%
Cash & Equivalents
$39.6M
↑ 42.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/10/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| 4 | 6/22/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NKTX |
| Company Name | Nkarta, Inc. |
| CIK | 1787400 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (925) 407-1049 |